Pfizer: more than six-fold increase in quarterly EPS

(CercleFinance.com) - Pfizer has announced adjusted EPS of $0.
63 for the last three months of 2024, compared with $0.10 a year earlier, on revenues up 22% to nearly 17.8 billion (+21% on an operating basis, including +11% excluding Covid-19 products).

The pharmaceutical giant confirms its targets for 2025, namely adjusted EPS of 2.80 to three dollars, as well as revenues of 61 to 64 billion, compared with adjusted EPS of 3.11 dollars and revenues of 63.6 billion achieved over the whole of 2024.

In addition, Pfizer says it has achieved its target of $4 billion in net cost savings under its cost realignment program, and has increased its total target to around $4.5 billion by the end of the current year.

Copyright (c) 2025 CercleFinance.com. All rights reserved.